title: Treatment of Guillain-Barré syndrome.
abstract: Guillain-Barré syndrome (GBS) is an idiopathic postinfectious immune disease that leads to progressive motor weakness due to damage to the myelin sheath. Epidemiological studies have linked GBS to infections from Campylobacter jejuni, Cytomegalovirus, and other pathogens. The syndrome includes multiple subtypes, with the most common being ascending motor weakness. Treatment with intravenous immunoglobulin and plasma exchange reduces the time for recovery to occur, although some remain disabled.
authors.affiliation: UCLA Health System, Los Angeles, California. Norma D. McNair, PhD, RN, CNRN, is the interim director of research and evidence-based practice for the UCLA Health System. She was formerly a clinical nurse specialist at Ronald Reagan UCLA Medical Center in Los Angeles, California.
authors.forename: Norma D
authors.initials: ND
authors.lastname: McNair
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D020275:Guillain-Barre Syndrome / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D010956:Plasmapheresis; D013041:Specialties, Nursing
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous